0001095981 2026-05-29 2026-05-29 0001095981 1 2026-05-29 2026-05-29 0001095981 2 2026-05-29 2026-05-29 0001095981 3 2026-05-29 2026-05-29 0001095981 4 2026-05-29 2026-05-29 0001095981 5 2026-05-29 2026-05-29 0001095981 6 2026-05-29 2026-05-29 0001095981 7 2026-05-29 2026-05-29 0001095981 8 2026-05-29 2026-05-29 0001095981 9 2026-05-29 2026-05-29 0001095981 1 2026-05-29 2026-05-29 0001095981 2 2026-05-29 2026-05-29 iso4217:USD pure shares S-3 S-3 EX-FILING FEES 0001095981 PLUS THERAPEUTICS, INC. N/A 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 0.0001381 true false S-3 PLUS THERAPEUTICS, INC. Equity Common Stock, $0.001 par value per share true Equity Preferred Stock, $0.001 par value per share true Other Warrants true Debt Debt Securities true Other Depositary Shares true Other Stock Purchase Contracts true Other Subscription Rights true Other Units true false Unallocated (Universal) Shelf true 100000000.00 0.0001381 13810.00 100000000.00 13810.00 0.00 13810.00 0.00 (1) There are being registered hereunder such indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities, such indeterminate number of warrants to purchase common stock, preferred stock or debt securities, such indeterminate number of shares of common stock issuable pursuant to subscription rights and such indeterminate number of units as may be sold by the registrant from time to time, which together shall have an aggregate initial offering price not to exceed $100,000,000. If any debt securities are issued at an original issue discount, then the principal amount of such debt securities shall be in such greater amount as shall result in an aggregate initial offering price not to exceed $100,000,000, less the aggregate dollar amount of all securities previously issued hereunder. Any securities registered hereunder may be sold separately or in combination with other securities registered hereunder. The securities registered also include such indeterminate number of shares of common stock and preferred stock and amount of debt securities as may be issued upon conversion of or exchange for preferred stock or debt securities that provide for conversion or exchange, upon exercise of warrants or pursuant to the antidilution provisions of any such securities. In addition, pursuant to Rule 416 under the Securities Act, the shares being registered hereunder include such indeterminate number of shares of common stock and preferred stock as may be issuable with respect to the shares being registered hereunder as a result of stock splits, stock dividends or similar transactions. (2) The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended. true Plus Therapeutics, Inc. S-3 333-286393 2025-04-04 13810.00 Equity Common Stock, par value $0.001 per share 0 0.00 true Plus Therapeutics, Inc. S-3 333-286393 2025-04-04 194082.78 the Prior Registration Statement was not declared effective, no securities were sold thereunder. A filing fee of $194,082.78 was previously paid in connection with the registration statement on Form S-3 (No. 333-286393) filed by the registrant on April 4, 2025 (the "Prior Registration Statement"). The registrant withdrew the Prior Registration Statement by filing a Form RW on June 23, 2025. As the Prior Registration Statement was not declared effective, no securities were sold thereunder. As of the date of this registration statement, an aggregate of $9,958.65 of the unused filing fees previously paid by the Registrant in connection with the filing of the Prior Registration Statement have been offset to pay for other filing fees due. Accordingly, $184,124.13 of the filing fees previously paid in connection with the Prior Registration Statement remains available to be used to offset the fee currently due and additional fees that may become due for future registration statements. In accordance with Rule 457(p) of the Securities Act, such previously paid filing fee will offset the filing fee of $13,810.00 currently due pursuant to this registration statement.